

# Pharmaceutical Benefits Scheme (PBS) Listings

## 1 July 2025

Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on **1 July 2025**.

This information relates to the administration of these listings by Services Australia. For further information on broader PBS changes, please visit the PBS website. Relevant information and authority application forms have been updated and can be accessed through the Services Australia website.

Please note, all remaining authority application forms have been updated to remove the title fields in the prescriber and patient details sections, as part of PBS listings changes in June 2025.

### **Cystic fibrosis**

Elexacaftor + tezacaftor + ivacaftor (&) ivacaftor (elexacaftor 100 mg + tezacaftor 50 mg + ivacaftor 75 mg granules [28] (&) ivacaftor 75 mg granules [28], 56 sachets; elexacaftor 80 mg + tezacaftor 40 mg + ivacaftor 60 mg granules [28] (&) ivacaftor 59.5 mg granules [28], 56 sachets; elexacaftor 50 mg + tezacaftor 25 mg + ivacaftor 37.5 mg tablet [56] (&) ivacaftor 75 mg tablet [28], 84; elexacaftor 100 mg + tezacaftor 50 mg + ivacaftor 75 mg tablet [56] (&) ivacaftor 150 mg tablet [28], 84) (Trikafta®) for the treatment of cystic fibrosis has had an update to restrictions. Authority applications for initial and continuing treatments can be made either in real-time using the Online PBS Authorities system or in writing.

### **Severe active rheumatoid arthritis; severe active juvenile idiopathic arthritis; severe psoriatic arthritis; severe chronic plaque psoriasis; ankylosing spondylitis**

Etanercept (50 mg/mL injection, 4 x 1 mL pen devices) (Nepexto®) is a biosimilar now listed on the PBS for the treatment of severe active rheumatoid arthritis, severe active juvenile idiopathic arthritis, severe psoriatic arthritis, severe chronic plaque psoriasis and ankylosing spondylitis.

### **Branch retinal vein occlusion with macular oedema; central retinal vein occlusion with macular oedema**

Faricimab (6 mg/0.05 mL intraocular injection, 0.05 mL syringe) (Vabysmo®) is now listed on the PBS for the treatment of branch retinal vein occlusion with macular oedema and central retinal vein occlusion with macular oedema. Authority applications for initial treatment can be made either in real-time using the Online PBS Authorities system or in writing. Prescriptions for continuing treatment are Authority required (STREAMLINED).

### **Early breast cancer**

Ribociclib (200 mg tablet) (Kisqali®) is now listed on the PBS for the treatment of early breast cancer. Authority applications for initial and continuing treatments can be made either in real-time using the Online PBS Authorities system or by telephone.

### **Locally advanced or metastatic cholangiocarcinoma**

Ivosidenib (250 mg tablet) (Tibsovo®) is now listed on the PBS for the treatment of locally advanced or metastatic cholangiocarcinoma. Prescriptions for treatment are Authority required (STREAMLINED).

### **Cytomegalovirus infection and disease**

Maribavir (200 mg tablet) (Livtencity®) is now listed on the PBS for the treatment of cytomegalovirus infection and disease. Prescriptions for treatment are Authority required (STREAMLINED).

### **Unresectable or metastatic urothelial carcinoma**

Nivolumab (40 mg/4 mL injection, 4 mL vial; 100 mg/10 mL injection, 10 mL vial) (Opdivo®) is now listed on the PBS for the treatment of unresectable or metastatic urothelial carcinoma. Prescriptions for initial and continuing treatments are Authority required (STREAMLINED).

### **Trachoma; urethritis; cervicitis**

Azithromycin (500 mg tablet) (Azithromycin Tablets, USP 500 mg (Precision Dose, USA)®) for the treatment of trachoma; urethritis and cervicitis is now listed on the PBS for the current supply shortage under Section 19A. Azithromycin is listed as a restricted benefit.

### **Attention deficit hyperactivity disorder**

Methylphenidate (18 mg; 27 mg; 36 mg; 54 mg modified release tablet) (Concerta (Switzerland)®) for the treatment of attention deficit hyperactivity disorder is now listed on the PBS for the current supply shortage under Section 19A. Authority applications can be made either in real-time using the Online PBS Authorities system or by telephone.

### **Bone pain; chronic arthropathies; severe pain**

Naproxen (125 mg/5 mL oral liquid, 474 mL) (Pediapharm Naproxen Suspension 25 mg/mL (Medexus Pharma, Canada)®) for the treatment of bone pain; chronic arthropathies (including osteoarthritis) and severe pain is now listed on the PBS for the current supply shortage under Section 19A. Prescriptions for the treatment of bone pain and chronic arthropathies (including osteoarthritis) are Authority required (STREAMLINED). Naproxen for the treatment of severe pain in palliative care is listed as a restricted benefit.

## **1 July 2025 delisted PBS listings**

### **Inflammation of the eye**

Dexamethasone (0.1% eye drops, 5 mL) (Maxidex®) has been delisted.

### **Prevention of chronic, stable angina pectoris due to coronary artery disease**

Glyceryl trinitrate (15 mg/24 hours patch) (Minitran 15®) has been delisted.

### **Systemic lupus erythematosus**

Anifrolumab (300 mg/2 mL injection, 2 mL vial) (Saphnelo®) no longer has a listing for Grandfather arrangements.

## **PBS Authorities – Changes from 1 July 2025**

We understand having access to PBS-subsidised medicines can be critical to patient care. That's why Services Australia and the Department of Health, Disability and Ageing are continuing to work together to increase the number of PBS medicines that can be requested and approved using the Online PBS Authorities system (the system).

From 1 July 2025, you will be able to use the system to apply for authority approval and provide evidence digitally for the following medicines. These changes will make it easier for you to request authority approval for these medicines from Services Australia. You will no longer need to submit the written authority application form, details of the proposed prescriptions and test results for certain medicines and treatment phases.

### **Treatment of severe psoriatic arthritis**

Authority applications for initial, grandfather (bimekizumab and risankizumab only), change or recommencement and continuing treatments with adalimumab, bimekizumab, certolizumab pegol, etanercept, golimumab, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tofacitinib, upadacitinib and ustekinumab can now be made either using the Online PBS Authorities system or in writing.

Authorities for subsequent continuing treatment with biosimilar brands of biological medicines are Authority Required (STREAMLINED).

## **Important Information**

### **Submitting Pharmaceutical Benefits Scheme (PBS) Written Applications through Health Professional Online Services (HPOS) form upload**

When submitting PBS authority forms through HPOS form upload, it is important to select the correct Form Category. For PBS patients, select PBS Authorities. For DVA patients, select RPBS Authorities. Remember that only yourself or your delegate/s are authorised to upload PBS and RPBS Authority applications.

Make sure you've:

- linked your prescriber number to your Provider Digital Access (PRODA) account for HPOS; and
- Set up your delegations in HPOS.

Visit [servicesaustralia.gov.au/HPOS](https://servicesaustralia.gov.au/HPOS) for more information on how to Link your Health Identifiers to HPOS and Manage delegations.

### **PBS Authorities items criteria**

Under the PBS, medicines are made available based on recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC). Patients must meet the set criteria to be eligible for PBS subsidised medicines. Services Australia are unable to provide approval for an Authority Required medication where a patient does not meet the criteria established by PBAC.

If you have concerns or questions about the eligibility criteria set by PBAC, you can contact the Department of Health, Disability and Ageing by email at [pbs@health.gov.au](mailto:pbs@health.gov.au).

## **Reminders**

### **PBS Authorities – written authority application forms**

To align with PBS listing changes, forms are updated on the first of the month. Using the most recent form will help avoid delays in obtaining authority approval.

### **Correct online authority number**

When prescribing PBS medicines via the Online PBS Authorities system, ensure you have selected the correct medicine to match what is on the prescription. This will avoid delays with providing patients with the medication they require.

### **Ensuring you are providing accurate data**

It's important to ensure you are providing accurate and up to date information when completing an authority application. Failure to do so may result in your authority request being rejected.

## **More information**

For more information about the Online PBS Authorities system visit [www.servicesaustralia.gov.au/hppbsauthorities](https://www.servicesaustralia.gov.au/hppbsauthorities)

Services Australia has a broad range of educational resources on the Health Professional Education Resources website. This includes simulations, podcast and an infographic on the Online PBS Authorities system. Visit <https://hpe.servicesaustralia.gov.au/pharmaceutical-benefits-scheme.html>

Visit [servicesaustralia.gov.au/hpwrittenauthoritydrugs](https://servicesaustralia.gov.au/hpwrittenauthoritydrugs) on the Services Australia website to find the most up to date authority application form for each drug, program or condition.